Safety of Intranasal Fentanyl (PecFent®) in the Treatment of Procedural Pain in the Elderly (FENTA)

May 2, 2018 updated by: University Hospital, Grenoble

Safety of Intranasal Fentanyl (PecFent®) in the Treatment of Procedural Pain in the Elderly With or Without Background Treatment.

The purpose of this study is to evaluate the safety of the intranasal fentanyl in pain induced by wound care and rehabilitation in the elderly. The project would also provide a preliminary assessment of the effectiveness of intranasal fentanyl used in procedural pains.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

This is a safety clinical trial. This trial is monocentric, open label, non-randomized.

Sixty elderly patients will be enrolled in this study, 30 with bedsore cares and 30 with rehabilitation sessions.

Six bedsore cares or rehabilitation sessions will be assessed for each subject. For each session, patient pain will be evaluated using a visual analogic scale VAS at different times, before session, 5 minutes then 20 minutes after the beginning of the session, and a last VAS 1 hour after the end of the session. During the two first sessions, patients do not receive Pecfent® to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care.

An evaluation of respiratory rate and of the level of sedation will occur at different time : after 5 minutes then 20 minutes of care, at the end of the care session,at half an hour then one hour after the care session.

At the end of sessions,

  • The nurse or physiotherapist will assess their satisfaction regarding the objectives achieved during the session with a four points verbal descriptor scale (very satisfied, satisfied, not much satisfied, not satisfied). They will also evaluate at the end of the four last session their satisfaction regarding the convenience of the use of pecfent® and its contribution towards care.
  • Patients will assess their satisfaction regarding the course of the session with a verbal descriptor scale (VDS) and their level of anxiety felt during the session with a VAS.

Study Type

Interventional

Enrollment (Actual)

58

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Isere
      • Grenoble, Isere, France, 38043
        • University hospital of Grenoble

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

76 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Hospitalized geriatric patient requiring care or rehabilitation
  • Patient with pain during treatment or mobilization. (VAS ≥ 4)
  • Written Informed consent

Exclusion Criteria:

  • All unstable fractures
  • Confusion: unable to assess their level of pain using a VAS.
  • Contraindications to PecFent ® (. Hypersensitivity to the active substance or to any of the excipients listed in section Composition Use in patients who had never received treatment for opioid severe respiratory depression or severe obstructive pulmonary disease.)
  • Person under legal protection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intranasal fentanyl
During the two first sessions of care or rehabilitation, patients do not receive Pecfent® in order to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care. A titration of PecFent will be done at each session

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety of intranasal fentanyl as measured by the nature and frequency of adverse effects.
Time Frame: 5 days after the last intake of fentanyl.
The nature and frequency of adverse effects will be described. The collection of adverse events will be first, with the collection of spontaneous patient complaints from nurses on the other hand, by systematic screening with the patient. Monitoring of respiratory rate and level of sedation will also be set up.
5 days after the last intake of fentanyl.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effectiveness of intranasal fentanyl in procedural pain using a VAS (Visual Analogic Scale) of pain.
Time Frame: Evolution of the level of pain (VAS) since the beginning of care until one hour after the end of session (on average at 2 hours).
VAS will be evaluated during each session at t0, t0+15min, t0+30min, and 1hour after the session (on average at 2 hours)
Evolution of the level of pain (VAS) since the beginning of care until one hour after the end of session (on average at 2 hours).
Fentanyl impact on the goals of care as measured by a caregiver satisfaction scale.
Time Frame: At the end of session of care or rehabilitation (on average at 1 hour).
At the end of each session of care or rehabilitation, it will be proposed to the caregiver, a scale measuring its satisfaction regarding the objectives achieved during the session.
At the end of session of care or rehabilitation (on average at 1 hour).
Nurse or physiotherapist satisfaction regarding use of PecFent® as measured by a verbal descriptor scale
Time Frame: 1 hour after the last intake of fentanyl
Nurse or physiotherapist evaluation satisfaction regarding the convenience of the use of pecfent® and its contribution towards care using a verbal descriptor scale
1 hour after the last intake of fentanyl
Impact of PecFent® on patient feelings during care or rehabilitation sessions as measured by a verbal descriptor scale
Time Frame: At the end of Session of care or rehabilitation (on average at 1 hour).

Patient evaluation at the end of sessions:

- Patient satisfaction regarding the course of the session with a VDS

At the end of Session of care or rehabilitation (on average at 1 hour).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 8, 2014

Primary Completion (Actual)

October 24, 2017

Study Completion (Actual)

April 1, 2018

Study Registration Dates

First Submitted

October 13, 2014

First Submitted That Met QC Criteria

November 19, 2014

First Posted (Estimate)

November 24, 2014

Study Record Updates

Last Update Posted (Actual)

May 8, 2018

Last Update Submitted That Met QC Criteria

May 2, 2018

Last Verified

May 1, 2018

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain Due to Certain Specified Procedures

Clinical Trials on intranasal fentanyl

3
Subscribe